Contract Pharm 合同定制服务展12月重临上海

  • Contract Pharm,合同定制服务展,医药合同定制,上海世博展览馆
  • 生物探索

Contract Pharm 合同定制服务展(2014第三届中国国际医药合同定制研发与生产服务展览会)将于2014年12月23日-25日在中国上海世博展览馆举办,蓄势待发。显赫往绩,展出面积突破两万。

Contract Pharm 合同定制服务展已成功举办两届。Contract Pharm 合同定制服务展暨2014第二届中国国际医药合同定制研发与生产服务展览会已于6月20日顺利闭幕。Contract Pharm 合同定制服务展展会吸引了来自德国、日本、美国、意大利、香港、台湾省等国家和地区的100多家企业参展,展馆面积超过5000平米,吸引观众10,187人次,集中展示了合同研发,医药原料及中间体制造、制剂生产,精细及专用化学品、生物制药及临床试验用药的定制合成、委托加工等合同定制行业最新产品及技术。

2014年12月23日-25日,Contract Pharm 合同定制服务展强势回归上海世博展览馆,众多展商、观众、媒体纷纷表示将一如既往支持展会。规模再攀新高,预计展会规模将达2万平方米,届时将汇集来自15多个国家和地区的200余家企业,以更大规模、更多展商、更全面的展示范围吸引近10000名海内外专业观众和消费人群莅临现场。


深度接触用户行业,尽享最佳推广服务

Contract Pharm 合同定制服务展将围绕应用行业,举办具有针对性的团体参观、采购洽谈、技术研讨、VIP观众一对一邀请等活动,集中为展商提供直面重点用户的机会。


全面影响用户行业

关注买家组织,邀请本土及全球全行业用户企业参与,包括来自医药和生物技术、研发合成、工业生产、药品监管、生产监管、工业流程设计、质量监控、规章管理、管理外包、战略合作、包装生产、物流配送、市场营销、临床前开发、临床试验、法规咨询、供应链及采购等领域的企业高管、项目负责人以及专家学者等。


特邀买家商务配对

针对您的目标用户行业,主办方为您一对一特别邀请潜在买家,到现场与您面对面交流。特邀买家商务配对活动受到业界的大力欢迎,众多特邀买家在现场与参与展商达成了采购意向,提高了效率并节省了时间和差旅成本。商务配对服务是提升您销售的得力助手。


买家参观团

重点邀请各大药厂研发部专业观众参观,并特邀大中专科研机构人员参观展会组成买家参观团,国际上通过在中国的外国商会及使馆组织跨国药企及科研相关部门组成国际采购商,如来自美国、加拿大、英国、瑞士、新加坡、印度及中国台湾等20多个国际和地区参观团将受邀参观展会,并参与商务配对活动。三大展示主题,覆盖合同定制服务全产业链

Contract Pharm 合同定制服务展将集中展示合同研发外包(CRO);合同生产外包(CMO);合同销售外包(CSO)三大展示主题,为国内合同定制服务行业供需双方提供一个信息传播、技术交流和贸易洽谈的优质平台。

Contract Pharm 合同定制服务展同期举办多场高端峰会论坛、贸易采购洽淡会、新产品新技术发布会、人才交流会等主题活动,聚焦行业热点,汇聚全球瞩目,吸引来自行业内的500多家企业参与。为鼓励医药行业企业充分发挥积极性和创造性,加快高新科技成果转化为生产力的步伐,增强市场竞争力,推动我国医药产业创新发展,由PI《医药界》杂志、国际医药资源网还将在上海世博展览馆组织发起“2014中国医药行业创新力企业TOP100评选”活动。2014中国医药行业创新力企业TOP100榜单发布主要表彰在某一技术领域具有重大创新,有良好市场潜力、经济性好的医药企业。

This link:http://www.chemcd.com/news/1820.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus

Categories

Related News

Prime Therapeutics urges FDA to keep current, consistent naming conventions for biologics, biosimilars

Prime Therapeutics, LLC (Prime) has submitted comments to the U.S. Food and Drug Administration (FDA) in support of two citizen petitions on the naming of biosimilar drugs. Biosimilars are medically equivalent versions of biologics, used to treat complex illnesses such as cancer.

FDA Approves Pembrolizumab for Advanced Melanoma

Today the FDA approved Keytruda (pembrolizumab), a new treatment for advanced melanoma, the deadliest form of skin cancer. Melanoma patients have been waiting anxiously for this day, given the promising data that early studies have shown.

Epoxy Resin Market Worth $9.2 Billion by 2019

"Epoxy Resin market by Application (Coatings, Electronics, Construction, Wind Turbine, Composites, and Adhesives) and Geography - Trends & Forecast to 2019" by MarketsandMarkets, the market of epoxy resin is projected to grow from an estimated $5,995.8 million in 2013 to $9,219.1 million by 2019, with a CAGR of 7.4% between 2014 and 2019.

GSK receives FDA approval of an additional Promacta (eltrombopag) indication for use in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST)

FDA has approved a supplemental New Drug Application (sNDA) for the once-daily use of Promacta(eltrombopag) in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST).

FDA Approves The Medicines Company's ORBACTIV™ (oritavancin) for Use in Acute Bacterial Skin and Skin Structure Infections

FDA Approves The Medicines Company's ORBACTIV? (oritavancin) for Use in Acute Bacterial Skin and Skin Structure Infections First and Only Single Dose Antibiotic for the Treatment of Skin Infections Caused by Susceptible Designated Gram-positive Bacteria ORBACTIV?U.S. Launch Expected in 2H/2014

AstraZeneca and QIAGEN enter collaboration to develop diagnostic test for lung cancer patients suitable for treatment with IRESSA

AstraZeneca today announced that it has entered into a collaboration with Netherlands-based QIAGEN to develop a non-invasive diagnostic test to identify non-small cell lung cancer (NSCLC) patients who are suitable for treatment with IRESSA?.

Scientists test nanoparticle 'alarm clock' to awaken immune systems put to sleep by cancer

Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center are exploring ways to wake up the immune system so it recognizes and attacks invading cancer cells. Tumors protect themselves by tricking the immune system into accepting everything as normal, even while cancer cells are dividing and spreading.